LONDON--(BUSINESS WIRE)--Technavio has announced their latest pipeline analysis report on the myocardial fibrosis market. The report includes a detailed analysis of the pipeline molecules under investigation within the defined data collection period to treat myocardial fibrosis.
This report by Technavio presents a detailed analysis of the market, including regulatory framework, drug development strategies, recruitment strategies, and key companies that are expected to play an essential role in the growth of the market in the future.
This report is available at a USD 1,000 discount for a limited time only: View market snapshot before purchasing
Myocardial fibrosis: Market overview
Myocardial fibrosis, also known as cardiac fibrosis, is a condition that involves the impairment of the heart’s muscle cells called myocytes. It belongs to a class of diseases collectively known as fibrosis, which is defined by the solidifying or scarring of tissue. Myocardial fibrosis not only affects the heart but also other organs, such as the lungs and liver.
According to a senior market research analyst at Technavio, “In myocardial fibrosis, myocytes are replaced by tissue that is unable to contract. This happens when fibroblasts, which produce collagen to enable wound healing, generate excessive amounts of the protein. Thus, the rising incidence of myocardial fibrosis is expected to boost the drug development for myocardial fibrosis throughout the predicted period.”
Myocardial fibrosis: Segmentation analysis
This pipeline analysis report segments the myocardial fibrosis market based on therapies employed (monotherapy), RoA (oral, and parenteral), therapeutic modality (small molecule, protein, peptide, endoglin antibody, stem cell, and RNA), targets (galectin-3, BMP, collagen, ERβ, ET-1, methotrexate, NPR-C, Proline tRNA synthetase, RhoA, soluble epoxide hydrolase, and TGF-β), MoA (galectin-3 inhibitor, BMP inhibitor, cell replacement, collagen modulator, ERβ agonists, ET-1 agonist, methotrexate inhibitor, NPR-C agonists, Proline tRNA synthetase inhibitor, RhoAGEF12 inhibitor, soluble epoxide hydrolase inhibitors, and TGF-β modulator), and recruitment status (not yet recruiting). It provides an in-depth analysis of the prominent factors influencing the market, including drivers, opportunities, trends, and industry-specific challenges.
Based on therapeutic modality, around 43% of the molecules that are being investigated for the treatment of myocardial fibrosis are small molecule.
Looking for more information on this market? Request a free sample report
Technavio’s sample reports are free of charge and contain multiple sections of the report such as the market size and forecast, drivers, challenges, trends, and more.
Some of the key topics covered in the report include:
Scope of the Report
Drug Development Landscape
- Drugs under development
- Indications coverage
Drug Development Strategies
- Therapies employed
- Therapeutic modality
- Geographical coverage
- Recruitment status
- Type of players
- Company overview
Discontinued or Dormant Molecules
Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.
With over 500 specialized analysts, Technavio’s report library consists of more than 10,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
If you are interested in more information, please contact our media team at email@example.com.